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REMARKS BY JON SODERSTROM* 
Senator Birch Bayh has made the most significant impact on the U.S. and 
global economy of any individual who has ever come before and who lives 
today, full stop.  That’s an amazing accomplishment.  We have heard about 
all the legislative feats that he accomplished.  We’ve heard about what an 
amazing legislator, attorney, and public servant he was.  But, there are very 
few human beings who have had the impact on our economy that Senator 
Bayh had.  It’s an amazing accomplishment and something that we should be 
in awe of. 
I’m going to give you a few statistics.  I’m not going to overwhelm you; 
I’m going to bring it down to a personal level.  I promised Kitty that I 
wouldn’t cry.  Because when I was thinking about this the other day, it’s 
hard.  If you knew Senator Bayh, he wore his emotions on his sleeve, and we 
have cried together. 
Here are just a couple statistics that should blow you away.  The Bayh-
Dole Act1 unleashed the technologies that were being developed in 
universities in a way that no one probably could have imagined.  It was 
immediate and it was dramatic.  The year was 1980.  Prior to 1980—and I 
know because my entire career arc has followed the senator’s 
accomplishments—I was at graduate school studying the economy and what 
patents were doing, et cetera.  At that time, the federal government, by law, 
was the owner of all intellectual property created with federal dollars and, as 
a result, it had created 28,000 patents.2  Less than 5 percent of those patents 
had ever been licensed or commercialized, compared with 25 percent to 30 
percent of the small number of federal patents for which the government had 
allowed companies to retain title to the invention.3  That is “because the 
government would only grant nonexclusive licenses to patents it owned,” so 
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“a wall was erected between academic and corporate research.”4  Companies 
refused to invest the significant time and resources needed to receive 
regulatory approval in nascent technologies that could be simply copied by 
others, especially foreign firms, obtaining the same nonexclusive license.  
Research was often described in this period as being “contaminated” by 
federal funding because of the government’s licensing policies.5  In spite of 
the fact that a large portion of that was spent on the Department of Health 
and Human Services and the National Institutes of Health, no drug could 
trace its lineage to a patent license based on research that had been supported 
by the federal government.6  That’s before Bayh-Dole. 
From 1980 on, things changed.  Universities became the owners of the 
patents, and the reason was simple:  Senator Bayh recognized that you needed 
to put the intellectual property in the hands of the people who actually 
invented it.  Those are the people who understand it; those are the people who 
are passionate about it; those are the people who had the perseverance.  They 
would be the ones who would drive things forward.  Subsequent to the 
passage of the law, over 12,000 new companies were started.7  Interestingly 
enough, over 6000 of those companies still exist.8  Many of them are 
household names that you would recognize, such as Genentech and Amgen, 
just in the life sciences area.  Importantly, 153 new drugs have been 
discovered, have gone through the clinical development process, and are on 
the market after receiving Food and Drug Administration (FDA) approval.9 
I’m going to talk to you about one.  I’m going to use it to show what 
happened and why this law is so important.  There was a scientist at Yale 
University, where I’ve worked for many years now.  His name was William 
Prusoff.  In the 1950s, he had this amazing insight about how to create new 
types of drugs to combat infectious disease by interfering with the DNA-
synthesis mechanism.10  He invented the very first antiviral drug,11 but no 
one filed a patent.  It was to cure a form of blindness that was caused through 
a defect in a DNA mechanism.12  It never got commercialized; nobody cared 
and nobody did anything with it. 
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Now, we’re in 1984 and many of you here will remember what the crisis 
of the 1980s was:  AIDS.  Nobody knew what it was or how it was 
transmitted.  It was a death sentence.  If you got it, you were going to die.  
The only question was when.  There were no drugs to treat it because nobody 
knew how it worked.  Many academic medical centers, like my own, 
mobilized resources to start to understand exactly how the virus was 
transmitted and replicated and how it attacked the body’s immune system.  
They started to try everything they could possibly think of to stop it.  Nothing 
worked. 
Lo and behold, two scientists at Yale—Bill Prusoff and Tai-Shun Lin—
went into the freezer and found a compound called stavudine that had been 
developed many years before but had not been commercialized.13  It had just 
been distributed among academics.14  It had been developed by Jerome 
Horowitz at the Karmanos Cancer Center in Detroit.15  He thought it would 
be a cancer drug, but it failed.16  Inspired by Bill’s pioneering work in the 
1950s on antiviral therapy for disease treatment, he and Dr. Lin decided to 
try it to treat the AIDS virus.17  They discovered this was the first time any 
chemical had ever killed the virus with this level of activity.18 
There were a couple of problems, including that this was not a drug that 
could be used on humans and that it was very difficult to make.19  Because 
the two scientists had developed a relationship with Bristol Myers Squibb 
(BMS) and the Bayh-Dole Act encouraged researchers to work with 
companies to license patent rights for work they did, they approached BMS 
and asked if they would be interested in working on the drug.20  BMS said 
they would be interested if the scientists could solve those problems.21  Over 
the next nine months to a year, they solved all of the problems.22  In 1984, 
BMS took the drug, finished the preclinical development package, went to 
the FDA, and got the first fast-track approval for this drug.23  It became 
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known as Zerit.24  It was the very first effective medication against HIV-
AIDS.  It also became the very first component of what became the AIDS 
three-drug “cocktail.”25  With that, what was a death sentence became a 
manageable disease.  That’s amazing.  That has saved millions of lives. 
In 1980, when Senator Bayh was advocating for this change, he was doing 
so because it just seemed like the right thing to do—to unleash the 
entrepreneurial spirit behind this intellectual property.  What he didn’t realize 
was the impact it was going to have on individuals all over the world.  This 
drug, Zerit, which has now been followed by even better variations, ended 
up stemming the AIDS crisis in Africa, eastern Asia, and other parts of the 
developed world.26  This was a miracle.  None of this would have been 
possible without the Bayh-Dole Act. 
Subsequent to that, the Bayh-Dole Act has created about a trillion dollars’ 
worth of economic activity and 5.8 million jobs.27  Think about those 
statistics for a minute.  This is incredible for a small piece of legislation for 
which he is hardly even recognized.  Everybody knows about Senator Bayh’s 
work on various amendments to the Constitution, which was great.  But this 
Act changed lives, and I’m one of them.  Thank you. 
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